Exagen to Participate in Canaccord Genuity 13th Annual MedTech & Diagnostics Forum on November 21, 2019
November 07 2019 - 8:14AM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
debilitating and chronic autoimmune diseases by enabling timely
differential diagnosis and optimizing therapeutic intervention,
today announced that Ron Rocca, CEO of Exagen, will be
participating in the 13th Annual Canaccord Genuity Medical
Technology and Diagnostics Forum on Thursday, November 21 in New
York City. Mr. Rocca’s presentation will take place at 11:30 a.m.
EST.
A live audio webcast of the Canaccord Genuity presentation will
be available online from the investor relations section of the
Exagen website at https://investors.exagen.com/ or through the
following link: http://wsw.com/webcast/canaccord37/xgn/
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis.
CONTACTS:
InvestorsWestwicke Partners Mike
CavanaughMike.Cavanaugh@westwicke.com646.677.1838
MediaExagen Inc. Kamal
AdawiKAdawi@exagen.com760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Sep 2023 to Sep 2024